Abraham AA, Tisdale JF. Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood. 2021 Sep 16;138(11):932-941. PMID: 34232993

Papapetrou EP, Schambach A. Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Mol Ther. 2016 Apr;24(4):678-84. PMID: 26867951.

Palstra RJ, de Laat W, Grosveld F. Beta-globin regulation and long-range interactions. Adv Genet. 2008;61:107-42. PMID: 18282504.

Tolhuis B, Palstra RJ, Splinter E, Grosveld F, de Laat W. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol Cell. 2002;10(6):1453-65. PubMed PMID: 12504019.

Sankaran VG, Xu J, Orkin SH. Advances in the understanding of haemoglobin switching. Br J Haematol. 2010 Apr;149(2):181-94. doi: 10.1111/j.1365-2141.2010.08105.x. Epub 2010 Mar 1. PMID: 20201948.

Oudelaar AM, Beagrie RA, Kassouf MT, Higgs DR. The mouse alpha-globin cluster: a paradigm for studying genome regulation and organization. Curr Opin Genet Dev. 2021;67:18-24. PubMed PMID: 33221670.

Trent RJ. Diagnosis of the haemoglobinopathies. Clin Biochem Rev. 2006;27(1):27-38. PubMed PMID: 16886045.

Weatherall DJ. Hemoglobinopathies worldwide: present and future. Curr Mol Med. 2008;8(7):592-9. PMID: 18991645.

Williams TN, Weatherall DJ, Newbold CI. The membrane characteristics of Plasmodium falciparum-infected and -uninfected heterozygous alpha(0)thalassaemic erythrocytes. Br J Haematol. 2002;118(2):663-70. PMID: 12139762.

De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H et al. ß-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. Mediterr J Hematol Infect Dis. 2017 Feb 20;9(1):e2017018. PMID: 28293406.

Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018 Mar 15;4:18010. PMID: 29542687.

Ross JM, Forte S, Soulieres D. Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials. Expert Opin Emerg Drugs. 2022;27(2):211-24. PMID: 35912835.

Wienert B, Martyn GE, Funnell APW, Quinlan KGR, Crossley M. Wake-up Sleepy Gene: Reactivating Fetal Globin for beta-Hemoglobinopathies. Trends Genet. 2018;34(12):927-40. PMID: 30287096.

Crossley M, Christakopoulos GE, Weiss MJ. Effective therapies for sickle cell disease: are we there yet? Trends Genet. 2022. Epub 20220804. doi: 10.1016/j.tig.2022.07.003. PubMed PMID: 35934593.

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K et al. Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature. 2010 Sep 16;467(7313):318-22.PMID: 20844535 .

Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001 Dec 14;294(5550):2368-71. PMID: 11743206.

Meisel R. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and ß-Thalassemia.N Engl J Med. 2021 Jun 10;384(23):e91.PMID: 34107195.

Higgs DR. The molecular basis of alpha-thalassemia. Cold Spring Harb Perspect Med. 2013;3(1):a011718. PMID: 23284078.

Higgs DR, Weatherall DJ. The alpha thalassaemias. Cell Mol Life Sci. 2009;66(7):1154-62. PMID: 19020805.

King AJ, Higgs DR. Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form of a-thalassemia. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):353-360.PMID: 30504332.

Jatavan P, Chattipakorn N, Tongsong T. Fetal hemoglobin Bart's hydrops fetalis: pathophysiology, prenatal diagnosis and possibility of intrauterine treatment. J Matern Fetal Neonatal Med. 2018;31(7):946-57. PMID: 28277912.

Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol. 2009 May;16(3):187-94. PMID: 19318943.

Giardine BM, Joly P, Pissard S, Wajcman H, DH KC, Hardison RC, et al. Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2021;49(D1):D1192-D6. PMID: 33125055.

Piel FB, Weatherall DJ. The alpha-thalassemias. N Engl J Med. 2014;371(20):1908-16. PMID: 25390741.

Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol. 2011;29(1):73-8. PubMed PMID: 21151124.

Papapetrou EP, Schambach A. Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Molecular Therapy. 2016;24(4):678-84. PMID: 26867951.

Pavani G, Amendola M. Targeted Gene Delivery: Where to Land. Front Genome Ed. 2020;2:609650. PubMed PMID: 347132341.

Porteus MH. A New Class of Medicines through DNA Editing. New England Journal of Medicine. 2019;380(10):947-59. PMID:30855744.

Feng YQ, Seibler J, Alami R, Eisen A, Westerman KA, Leboulch P, et al. Site-specific chromosomal integration in mammalian cells: Highly efficient CRE recombinase-mediated cassette exchange. Journal of Molecular Biology. 1999;292(4):779-85.PMID: 10525404.